Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis

Cancer

Volumn 115, Issue 11, 2009, Pages 2420-2429

  Vanderveen, Kimberly A ^a   Chen, Steven L ^a   Yin, Daixin ^b   Cress, Rosemary D ^a,b   Bold, Richard J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PUBLIC HEALTH INSTITUTE   (United States)

Author keywords

Adjuvant treatment; Outcomes; Pancreatic cancer; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGISTRY; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL; TUMOR DIFFERENTIATION; UNITED STATES;

ADENOCARCINOMA; AGE FACTORS; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SEX FACTORS;

EID: 66649112508     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24269     Document Type: Article

References (27)

1. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2002. Bethesda, Md: National Cancer Institute; 2005. Available at: http://seer.cancer.gov/csr/1975-2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005. Accessed April 24, 2008.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
3. Picozzi VJ, Pisters PW, Vickers SM, et al. Strength of the evidence: adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg. 2008;12:657-661.
4. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227-1234.
5. Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-180. (Pubitemid 47196512)
6. Bilimoria KY, Bentrem DJ, Tomlinson JS, et al. Quality of pancreatic cancer care at Veterans Administration compared with non-Veterans Administration hospitals. Am J Surg. 2007;194:588-593. (Pubitemid 47538460)
7. Govindarajan A, Tan JC, Baxter NN, et al. Variations in surgical treatment and outcomes of patients with pancreatic cancer: a population-based study. Ann Surg Oncol. 2008; 15:175-185.
8. Shaib Y, Davila J, Naumann C, et al. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J Gastroenterol. 2007;102:1377-1382. (Pubitemid 46976285)
9. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14:1320-1326. (Pubitemid 46536816)
10. Hofer BM, Kwong SL, Allen M, Bates JH, McCusker ME, Snipes KP. Cancer in California, 2008, Special Highlight on Cancer by Race and Ethnicity. Sacramento, CA: California Department of Public Health, Cancer Surveillance Section; 2008.
11. Cress RD, Yin D, Clarke L, et al. Survival among patients with adenocarcinoma of the pancreas: a population-basedstudy (United States). Cancer Causes Control. 2006;17:403-409.
12. Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H. Race, socio-economic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev. 2007;16:546-552 (Pubitemid 46548659)
13. Cleary SP, Gryfe R, Guindi M, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004;198:722-731. (Pubitemid 38542900)
14. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
15. Cress RD, Zaslavsky AM, West DW, Wolf RE, Felter MC, Ayanian JZ. Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care. 2003;41:1006-1012.
16. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12:703-711. (Pubitemid 32803497)
17. Kalser MH, Ellenber SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903. (Pubitemid 15040883)
18. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010. (Pubitemid 17077780)
19. Nightengale SL. From the Food and Drug Administration. JAMA. 1995;273:982.
20. Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999;85:1261-1268. (Pubitemid 29125078)
21. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative- intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277. (Pubitemid 46143304)
22. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782. (Pubitemid 30191812)
23. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210. (Pubitemid 38339364)
24. Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma [abstract]. J Clin Oncol. 2006;24(18S pt 1):4007. Abstract 4007.
25. Chang KJ, Parasher G, Christie C, Largent J, Anton-Culver H. Risk of pancreatic adenocarcinoma: disparity between African Americans and other race/ethnic groups. Cancer. 2005;103:349-357. (Pubitemid 40129295)
26. Longnecker DS, Karagas MR, Tosteson TD, Mott LA. Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in Asians, blacks, and whites in the United States. Pancreas. 2000;21:338-343.
27. Pernick NL, Sarkar FH, Philip PA, et al. Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians. Pancreas. 2006;26:28-32.